Preventing Infections with Acalabrutinib Plus Venetoclax
July 29, 2025
An ongoing phase 2 clinical trial is studying whether preemptive acalabrutinib plus venetoclax can prevent infections in newly diagnosed CLL patients.
An ongoing phase 2 clinical trial is studying whether preemptive acalabrutinib plus venetoclax can prevent infections in newly diagnosed CLL patients.
Adding early Obinutuzumab to Acalabrutinib-Venetoclax significantly increases rates of uMRD in the bone marrow of patients with treatment-naïve CLL.
The EU commission has approved acalabrutinib in combination with venetoclax, with or without obinutuzumab, for the frontline treatment of CLL.
As Inflation Reduction Act negotiations begin, CLL Society is ensuring CMS understands the importance of treatments for CLL patients and physicians.
Acalabrutinib, venetoclax, and obinutuzumab is a highly active, time-limited frontline therapy for patients with high-risk CLL.
The AMPLIFY trial of acalabrutinib plus venetoclax, with or without obinutuzumab, could lead to the FDA approval of the first all-oral frontline CLL therapy.
Acalabrutinib plus obinutuzumab had a 100 percent response rate at 14 months and a deep reduction of disease in the bone marrow in treatment-naive CLL.
Resistance mutations in BTK and PLCG2 are common in patients with CLL who progress on acalabrutinib, a BTK inhibitor treatment that is taken continuously.
An interim analysis of the AMPLIFY trial comparing acalabrutinib and venetoclax with or without obinutuzumab for CLL shows improvements in patient survival.